Head-To-Head Contrast: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)

ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings and Valuation

This table compares ARS Pharmaceuticals and Nutriband”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28 million	5.06	-$171.30 million	($2.18)	-1.97
Nutriband	$2.04 million	44.53	-$8.23 million	($0.53)	-14.09

Nutriband has lower revenue, but higher earnings than ARS Pharmaceuticals. Nutriband is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for ARS Pharmaceuticals and Nutriband, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1	1	4	0	2.50
Nutriband	1	1	0	0	1.50

ARS Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 482.75%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe ARS Pharmaceuticals is more favorable than Nutriband.

Risk and Volatility

ARS Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.

Profitability

This table compares ARS Pharmaceuticals and Nutriband’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
Nutriband	-430.35%	-109.07%	-95.54%

Summary

ARS Pharmaceuticals beats Nutriband on 8 of the 14 factors compared between the two stocks.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.